# EDGAR Filing Document

**Accession Number:** 0001593984
**File Stem:** 0001178913-23-000510
**Filing Date:** 2023-2
**Character Count:** 3279
**Document Hash:** fcfd873883e7c7f4c5b06843f22ed29e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-23-000510.hdr.sgml**: 20230213

**ACCESSION NUMBER**: 0001178913-23-000510

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230213

**FILED AS OF DATE**: 20230213

**DATE AS OF CHANGE**: 20230213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MediWound Ltd.
- **CENTRAL INDEX KEY:** 0001593984
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36349
- **FILM NUMBER:** 23614782

**BUSINESS ADDRESS:**
- **STREET 1:** 42 HAYARKON STREET
- **CITY:** YAVNE
- **STATE:** L3
- **ZIP:** 8122745
- **BUSINESS PHONE:** 97289324010

**MAIL ADDRESS:**
- **STREET 1:** 42 HAYARKON STREET
- **CITY:** YAVNE
- **STATE:** L3
- **ZIP:** 8122745

------

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 6-K

#### REPORT OF FOREIGN PRIVATE ISSUER

#### Pursuant to Rule 13a-16 or 15d-16 of the

#### Securities Exchange Act of 1934

#### For the month of February 2023

#### Commission File Number: 001-36349

### MediWound Ltd.
(Translation of registrant's name into English)

#### 42 Hayarkon Street

#### Yavne, 8122745 Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): __ <br>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7): __

------

#### CONTENTS
MediWound Ltd. (the "Company") is filing this Form 6-K to disclose open market purchases of its ordinary shares by officers of the Company. On February 09, 2023, Nachum (Homi) Shamir, the Company's chairman of the board, and Ofer Gonen, the Company's CEO, purchased a total of 7,200 ordinary shares of the Company in open market transactions at an average price per share of $13.565. The ordinary shares were purchased in compliance with all relevant requirements of the Company's Insider Trading Policy.

The contents of this Form 6-K (including the information contained in Exhibit 99.1) are hereby incorporated by reference into the Company's Registration Statements on Form S-8, filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 and August 9, 2022 (Registration Nos. 333-195517, 333-210375, 333-223767, 333-195517, 333-210375, 333-230487, 333-236635, 333-255784, and 333-266697, respectively), and Form F-3, filed with the SEC on May 25, 2022 (Registration No. 333-265203).

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| Date: February 13, 2023 | MEDIWOUND LTD.<br>By: <u>/s/ Boaz Gur-Lavie</u><br> Name: Boaz Gur-Lavie<br> Title: Chief Financial Office |

---

------

<br>